# US 2013/0230901 A1 · Process for making recombinant antidote to factor xa inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0230901 A1
- Document ID: US20130230901A1
- Status: Published application
- Kind: A1
- Application number: 13/766,652
- Filed: 2013-02-13
- Published: 2013-09-05
- Earliest claimed: 2012-02-14
- Assignees: Portola Pharmaceuticals, Inc.
- Applicants: Portola Pharmaceuticals, Inc.
- Inventors: Genmin LU; Pamela B. Conley; Uma Sinha
- Web page: https://patentgrep.com/patent/US20130230901A1

## CPC

- C12N 9/6432: {Coagulation factor Xa (3.4.21.6)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12N 9/64: derived from animal tissue
- C12N 9/6454: {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
- C12Y 304/21006: Coagulation factor Xa (3.4.21.6)
- C12N 2510/02: Cells for production
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.

## Claims

### Claim 1

An isolated cell comprising:
a first polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and
a second non-endogenous polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.

### Claim 2 (depends on 1)

The isolated cell of claim 1, wherein the cell is selected from the group consisting of a bacterial cell, a mammalian cell and a yeast cell.

### Claim 3 (depends on 2)

The isolated cell of claim 2, wherein the cell is a mammalian cell.

### Claim 4 (depends on 3)

The isolated cell of claim 3, wherein the mammalian cell is a cell-type selected from the group consisting of CHO, COS, BHK, and HEK 293.

### Claim 5 (depends on 4)

The isolated cell of claim 4, wherein the cell-type is CHO.

### Claim 6 (depends on 5)

The isolated cell of claim 5, wherein the cell is a CHO cell subtype selected from the group consisting of K, M and DG44.

### Claim 7 (depends on 2)

The isolated cell of claim 2, wherein the cell is a bacterial cell.

### Claim 8 (depends on 7)

The isolated cell of claim 7, wherein the bacterial cell is E. coli.

### Claim 9 (depends on 1)

The isolated cell of claim 1, further comprising a selectable marker.

### Claim 10 (depends on 9)

The isolated cell of claim 9, wherein the selectable marker provides resistance to a compound selected from the group consisting of puromycin, methotrexate, neomycin and hygromycin.

### Claim 11 (depends on 10)

The isolated cell of claim 10, wherein the selectable marker provides resistance to methotrexate.

### Claim 12 (depends on 10)

The isolated cell of claim 10, wherein the selectable marker provides resistance to puromycin.

### Claim 13 (depends on 12)

The isolated cell of claim 12, wherein the selectable marker provides antibiotic resistance to the cell.

### Claim 14 (depends on 1)

The isolated cell of claim 1, wherein the first or second polynucleotide is on an extrachromosomal DNA construct.

### Claim 15 (depends on 1)

The isolated cell of claim 1, wherein the first or second polynucleotide is on a DNA construct integrated into the chromosomal DNA of the isolated cell.

### Claim 16 (depends on 1)

The isolated cell of claim 1, wherein the first and second polynucleotides are on one DNA plasmid.

### Claim 17 (depends on 1)

The isolated cell of claim 1, wherein the wherein the first and second polynucleotides are on different DNA plasmids.

### Claim 18 (depends on 1)

The isolated cell of claim 1, further comprising
a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and
a second polypeptide comprising the amino acid sequence of SEQ ID NO: 3 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 3.

### Claim 19 (depends on 18)

The isolated cell of claim 18, wherein the ratio of the second polypeptide to the first polypeptide is at least about 8:2.

### Claim 20 (depends on 18)

The isolated cell of claim 18, wherein the ratio of the second polypeptide to the first polypeptide is at least about 9:1.

### Claim 21 (depends on 1)

The isolated cell of claim 1, further comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.

### Claim 22 (depends on 21)

The isolated cell of claim 21, wherein expression level of the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 is at least 3 times expression level of endogenous Furin.

### Claim 23 (depends on 1)

A composition comprising the isolated cell of claim 1 and cell culture media.

### Claim 24

A method of preparing a cleaved two chain polypeptide comprising the amino acid sequence of SEQ ID NO: 3 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 3, wherein the method comprises expressing in an isolated cell:
a first polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and
a second non-endogenous polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cell is selected from the group consisting of a bacterial cell, a mammalian cell and a yeast cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cell is a mammalian cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein the mammalian cell is a cell-type selected from the group consisting of CHO, COS, BHK, and HEK 293.

### Claim 28 (depends on 24)

The method of claim 24, wherein the cell-type is CHO.

### Claim 29 (depends on 24)

The method of claim 24, wherein the cell is a CHO cell subtype selected from the group consisting of K, M and DG44.

### Claim 30 (depends on 25)

The method of claim 25, wherein the cell is a bacterial cell.

### Claim 31 (depends on 30)

The method of claim 30, wherein the bacterial cell is E. coli.

### Claim 32 (depends on 24)

The method of claim 24, further comprising expressing a selectable marker gene in the cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein the selectable marker provides resistance to a compound selected from the group consisting of puromycin, methotrexate, neomycin and hygromycin.

### Claim 34 (depends on 33)

The method of claim 33, wherein the selectable marker provides resistance to methotrexate.

### Claim 35 (depends on 33)

The method of claim 33, wherein the selectable marker provides resistance to puromycin.

### Claim 36 (depends on 35)

The method of claim 35, wherein the selectable marker provides antibiotic resistance to the cell.

### Claim 37 (depends on 24)

The method of claim 24, wherein the first or second nucleotide is expressed from an extrachromosomal DNA construct.

### Claim 38 (depends on 24)

The method of claim 24, wherein the wherein the first or second polynucleotide is expressed from a DNA construct integrated into the chromosomal DNA of the isolated cell.

### Claim 39 (depends on 24)

The method of claim 24, wherein the first and second polynucleotides are on one DNA plasmid.

### Claim 40 (depends on 24)

The method of claim 24, wherein the wherein the first and second polynucleotides are on different DNA plasmids.

### Claim 41 (depends on 39)

The method of claim 39, wherein the DNA plasmids are transfected into the isolated cell by polyfection.

### Claim 42 (depends on 41)

The method of claim 41, wherein the plasmid comprising the second polynucleotide is from about 1% to about 50% of total transfected DNA.

### Claim 43 (depends on 42)

The method of claim 42, wherein the plasmid comprising the second polynucleotide is from about 1% to about 30% of total transfected DNA.

### Claim 44 (depends on 43)

The method of claim 43, wherein the plasmid comprising the second polynucleotide is about 3% of total transfected DNA.

### Claim 45 (depends on 43)

The method of claim 43, wherein the plasmid comprising the second polynucleotide is about 10% of total transfected DNA.

### Claim 46 (depends on 43)

The method of claim 43, wherein the plasmid comprising the second polynucleotide is about 30% of total transfected DNA.

### Claim 47 (depends on 24)

The method of claim 24 further comprising isolating, from the cell, a protein fraction comprising a polypeptide having at least about 80% sequence identity to SEQ ID NO: 3.

### Claim 48 (depends on 47)

The method of claim 47, wherein the protein fraction further comprises a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1.

### Claim 49 (depends on 48)

The method of claim 48, wherein the ratio of the cleaved two-chain polypeptide of SEQ ID NO: 3 to the uncleaved polypeptide of SEQ ID NO: 1 is at least about 8:2.

### Claim 50 (depends on 48)

The method of claim 48, wherein the ratio of the cleaved two-chain polypeptide of SEQ ID NO: 3 to the uncleaved polypeptide of SEQ ID NO: 1 is at least about 9:1.

### Claim 51 (depends on 24)

The method of claim 24, wherein expression level of the polypeptide expressed from second polynucleotide is at least 3 times expression level of endogenous Furin.

### Claim 52 (depends on 24)

A preparation of two chain fXa derivative prepared with method of claim 24.

### Claim 53

A polynucleotide construct that comprises
a first polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1; and
a second polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.
